Answers are grounded in this paper and cite their sources.
Identifies EGFL6's prognostic role in esophageal carcinoma, suggesting a potential therapeutic target.
BACKGROUND: The EGF-like domain multiple 6 (EGFL6) has been documented as an oncogene across diverse cancer types. Despite its known importance in tumorigenesis, EGFL6's involvement in esophageal carcinoma (ESCA) remains largely unexplored. Herein, we integrated multi-source omics data to characterize EGFL6's expression landscape, biological functions, and immunological implications in ESCA-with a focus on its prognostic value. METHODS: To identify dysregulated basement membrane-related genes (BMRGs) in ESCA, we performed Venn overlap analysis on RNA-seq data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and a curated BMRG reference list. Weighted gene co-expression analysis (WGCNA) was used to identify EGFL6-related modules and functional enrichment of differentially expressed genes (DEGs) were identified via Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA). EGFL6-specific epigenetic (DNA methylation) and genetic alterations were validated using Methsurv and cBioPortal. Single-sample GSEA (ssGSEA) was applied to explore immune infiltration and its correlation with EGFL6. Prognostic significance of EGFL6 was examined via Kaplan-Meier and receiver operating characteristic (ROC) analyses. RESULTS: Venn overlap analysis indicated EGFL6 as a significantly overexpressed gene in ESCA that closely correlated with multiple clinical and pathological features. WGCNA and subsequent functional enrichment analysis revealed that EGFL6-related DEGs participate in critical biological processes. Kaplan-Meier analysis demonstrated that increased EGFL6 contributed to reduced disease-specific survival (DSS) and progression-free interval (PFI) in patients with ESCA. In vitro experiments confirmed that EGFL6 promotes ESCA by enhancing cell proliferation, invasion and regulating cell-cycle progression. CONCLUSION: EGFL6 is significantly upregulated in ESCA and is related to various clinical factors, immune modulation and reduced prognosis. EGFL6 could be identified as a novel prognostic biomarker and a viable therapeutic target for the development of personalized treatment approaches in ESCA.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: